SGX Listed Stock

BIOLIDICS LIMITED (SGX:8YY)


SGD 0.435
-0.085 / -16.35%
Share Price as of: 2020-07-15 17:16
Market / ISIN Code: Catalist / SGXE89830751
GICS® Sector / Industry Group / Industry: Health Care / Health Care Equipment & Services / Healthcare Equipment and Supplies


Biolidics Blogger ArticlesBIOLIDICS LIMITED Blogger Articles SGX Listed BIOLIDICS LIMITED (SGX:8YY) Blogger Articles 8YY.SI Blogger Articles
Governance For Stakeholders
Mak Yuen Teen
2020-07-15 09:22:31
Biolidics’ Disclosures are Simply Unacceptable
Updated on July 15, 2020 to correct the following statement: “c. Why did the company agree to give a full refund, including for the 13,000 test kits that had been delivered, given that Aytu had a binding commitment to buy 500,000 test kits? Why is that in the interest of the company?” The refund is for the deposits paid for undelivered kits. The company is not required to give a refund for the 13... Source
Governance For Stakeholders
Mak Yuen Teen
2020-07-15 08:08:32
Biolidics: Making an A*S of the Rules
By Mak Yuen Teen On July 14, 10.46 pm, Biolidics announced a five-year non-exclusive licensing agreement with Accelerate Technologies Pte Ltd (A*ccelerate), the commercialisation arm of A*STAR. The announcement said that the agreement was signed on Thursday, July 9. On Monday, July 13, 12.19 pm, a trading halt was called. Prior to the trading halt, the company’s share price had increased from 41... Source
Dr Tee (Ein55)
Dr Tee (Ein55)
2020-04-29 15:10:28
Healthcare Giant Stock Q&M Dental (骨肉相连)
Healthcare stocks (eg. hospital business, pharmaceutical companies, vaccine development, etc.) are having competitive advantages, therefore those with growing businesses are usually growth giant stocks. Between life and money, which is more important? The choice is clear (金钱诚可贵、生命价更高) to put life at a higher priority, therefore healthcare has been a high growth sector in most countries. Q&M Dental (SGX: QC7) is a young healthcare giant stock with focus in dental services. The company started business in year 1996, having main businesses in Singapore (79 branches), Malaysia and China.  For China, due to stronger competition and higher cost, subsidiary stock, Aoxin Q&M (SGX: 1D4) with poorer business there, is not a giant stock, not performing as go





Investment BloggerSG Investment BlogSG Invest BloggersBloggers Say








Your Say











Stock / REIT Search

Advertisement

Advertisement